Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Only 300K trading brings 16%UP...Imagine few millions ?
Always put your money where Billionaires are ......They can change the things in no time...
As of June 30, 2011, the Company had cash totaling $42.0 million. Stockholders' equity amounted to $46.4 million as of June 30, 2011.
I think Market tested yesterday for Women & Children. Now remains is the lionhearts ...Once it start..it will rocket..
$16 ? With 3 weeks to a U.S. Food & Drug Administration (FDA) decision on Adventrx Pharmaceuticals’ (ANX) Exelbine™, an enhanced formulation of the chemotherapy drug, vinorelbine, trading continues to be volatile. The reason?
Vista Capital Partners set a $7.50 price target on Adventrx shares in the latter part of June, two days after Rodman & Renshaw revised their target on the company upwards 355% to $16. Shares quickly leaped to a new 52-week high, on equally impressive volume.
Approval might come on this weekend !!
Happened with FDA - if review is done they can issue an approval prior to PDUFA date.
It happened with VRML, DNDN , KV.A and many others off the record.
Wall Street after admitting in CCU yesterday is now COOL & CALM...Breathing NORMAL
APPROVAL IS 100% WHY ?
FDA didnot raise any concern on ANX530 approval other than CMC. ie Expiration date and 12 months Stability Issue after manufacturing.
Last communication back in March 2010 from USFDA was regarding CMC,chemistry, manufacturing and controls (CMC) reason for the refusal to file.
http://ir.adventrx.com/phoenix.zhtml?c=75414&p=irol-newsArticle&ID=1396408&highlight=
ADVENTRX Announces 12-Month Stability Data Results for ANX-530
http://ir.adventrx.com/phoenix.zhtml?c=75414&p=irol-newsArticle&ID=1470734&highlight=
No fkg Sky going to fall!! Let others fear. Get this as much as u can
Liquidmetal Technologies, Inc., a Delaware corporation (“Liquidmetal”), entered into a Master Transaction Agreement with Apple Inc...
Exactly One year...
http://www.sec.gov/Archives/edgar/data/1141240/000110465910042867/a10-15357_18k.htm
FDA approval news will change the game ..
It is anticipated that a 510(k) application will be filed with the FDA
in approximately 90 days. Assuming no extended delays in FDA review,
approval of Altrazeal® exSALT(TM) could occur as early as the third
quarter of 2011. The antimicrobial segment of the North American
advanced wound care market is projected to grow in the next 5 years to
be in excess of $750 million with annual growth rates above 15%.
http://www.redorbit.com/news/health/1981422/uluru_inc_announces_agree...
NO RECESSION, NO DEBT WORRIES, ANX will get USFDA approval in 25 days and opening price would be $13
e-bay NON-EXCLUSIVE LICENSE shows in new filling
14. NEOMEDIA hereby grants to EBAY, effective immediately, for the INITIAL TERM, an irrevocable, nonexclusive, worldwide license, under the PATENT RIGHTS to use, make, have made, sell, offer to sell, modify, import, export, and otherwise offer, dispose of, distribute, display, advertise and/or promote any COVERED PRODUCT directly or indirectly through any channel, including through multiple tiers of distribution. The license grant herein also extends to EBAY THIRD PARTIES solely in their role as EBAY THIRD PARTIES. For the sake of clarity, the license granted herein does not extend to EBAY THIRD PARTIES except when they are performing in their role as an EBAY customer, buyer, seller, user, developer, manufacturer, promoter, advertiser, reseller, and/or distributor or as an EBAY developer, supplier, vendor or manufacturer that supplies or incorporates components, steps, features or portions of the COVERED PRODUCTS. The license is not otherwise sub-licensable.
15. At the time that NeuStar’s exclusive right to grant licenses to third parties with respect to 2D barcode Registry and Clearinghouse, under the “Amended and Restated License Agreement” dated January 22, 2010, has expired or reverted to a non-exclusive license right, then all such license rights shall automatically and immediately vest with EBAY and EBAY THIRD PARTIES on a non-exclusive and non-sublicenseable license basis consistent with, and retroactive to the effective date of, the license, release and covenant not to sue rights set forth in this Agreement. Nothing contained in this Paragraph is intended to, nor shall be construed to, expand EBAY’s rights with respect to the PATENT RIGHTS as otherwise set forth herein.
16. If NEOMEDIA acquires ownership or exclusive rights to U.S. Patent No. 6,101,534 and any related patents or applications, then such rights shall automatically and immediately vest with EBAY and EBAY THIRD PARTIES on a non-exclusive and non-sublicenseable license basis consistent with the license, release and covenant not to sue rights set forth herein for the SEARCH TECHNOLOGY portfolio. NEOMEDIA has no obligation to make any attempt to acquire any such patents or applications.
It is anticipated that a 510(k) application will be filed with the FDA
in approximately 90 days. Assuming no extended delays in FDA review,
approval of Altrazeal® exSALT(TM) could occur as early as the third
quarter of 2011.
http://www.redorbit.com/news/health/1981422/uluru_inc_announces_agreement_with_exciton_to_develop_antimicrobial_dressing/
Altrazeal..USFDA approval/Amelexanox for CANCER SORE..
http://www.uluruinc.com/press_releases/ULURU_Inc_Announces_Filing_of_a_510_k_%20for_Altrazeal_Collagen.pdf
Amlexanox 5% paste is used for the treatment of cancer sores. A Phase IV clinical study conducted in Northern Ireland and results confirmed that amlexanox 5% paste was effective in preventing the formation of an ulcer when used at the first sign or symptom of the disease. As of December 31, 2010, Contract Pharmaceuticals Ltd. Canada is the Company’s contract manufacturer for all markets, including the United States.
ULU PRICE TGT $2.16 COMPANY BUY BACK COMMON SHARES The company may force conversion of the convertible note if the common stock trades for a defined period of time at a price greater than $2.16.
STRONG BUY RECOMEDATIOB...appreciation upto 8times than current price
https://news.fidelity.com/news/news.jhtml?articleid=201107300853RTRSNEWSCOMBINED_TRE76T11U_1&IMG=N&cat=Top.Investing.RT&ccsource=rss-Top.Investing.RT
We have 30 Days left to take this in doble figure
Pre treading Opened at 1.50..touched 1.6
CORRECTION SEPT 1ST OR BEFORE
ADR are valued different than common stocks (always way heigher if ratio is more) and are under strict US SEC regulations.
Because of this, foreign companies are forced to create ADS, which represent the full rights of the common stock they are based on. ADS are then securely held by a bank or financial institution in the foreign company's country, at which point American depositary receipts (ADR) are created to represent the ADS and are listed on the desired American exchange.
ADR are typically the units investors buy and sell on U.S. exchanges. ADR represent the ADS units held by the custodian bank in the foreign company's home country. ADR can be issued against ADS at any ratio the company chooses. For example, ABC company could have ADR trading on the New York Stock Exchange (NYSE) These ADR could be issued at a rate of five ADR equal to one American Depository Share (5:1), or any other ratio the company chooses.
The underlying ADS, however, most often correspond directly to the foreign company's common shares. In other words, the ratio of ADS to common shares is usually one, while the ratio of ADR to ADS can be whatever a company decides to issue them at. In case of IRE it is 1:10.
PDUFA DATE AUGUST 1ST OR BEFORE
Adventrix had submitted an NDA for ANX-530 to the FDA in December 2009. On March 1, 2010 it announced that it had received a refusal-to-file letter from the FDA regarding that submission. In the letter, the FDA indicated that the data included in the December 2009 NDA submission from the intended commercial manufacturing site was insufficient to support a commercially-viable expiration dating period. The FDA identified only this one chemistry, manufacturing and controls (CMC) reason for the refusal to file. No clinical or nonclinical issues were otherwise identified.
COMPANY ALREADY CORRECTED THAT...RESUBMITTED NDA
The Drug: ANX-530 is a novel emulsion formulation of the chemotherapy drug vinorelbine. Navelbine, a branded formulation of vinorelbine, is approved in the U.S. to treat advanced non-small cell lung cancer as a single agent or in combination with cisplatin, and approved in the European Union, or EU, to treat non-small cell lung cancer and advanced or metastatic breast cancer. Adventrix’ formulation emulsifies vinorelbine into a homogeneous suspension of nanoparticles that protects the venous endothelium during administration into a peripheral vein, thereby reducing irritation associated with administration of the drug. ANX-530 is supposed to lower the risk of phlebitis, erythema and pain at the site of injection, which occur in one third of patients treated with Novelbine, or its generic version.
YOU CAN'T STOP IF IT CROSS $3 TODAY
Watsa's genius—his single most important investment insight of the past five years—was to recognize that the new gnomes of finance had got it all wrong. Their fancy securitization schemes, which packaged up mortgages and consumer debt into bonds, weren't reducing risk; they were increasing it.
Buffett has received a lot of credit lately for calling derivatives "financial weapons of mass destruction" way back in 2003. But Watsa was every bit as prescient in seeing the weaknesses of what Wall Street euphemistically calls "structured finance." "Take the case of an automobile dealer," Watsa wrote to shareholders in early 2004. "Prior to securitization, the dealer would be very concerned about who was given credit to buy an automobile. With securitization, the dealer (almost) does not care, as these loans can be laid off through securitization." And the triple-A credit ratings given to thousands of these asset-backed bonds? A mirage, Watsa suggested. The default rates on them "will likely be very different in the future—particularly if we experience difficult economic times." About the only thing missing from his treatise was the word "subprime."
But it took years for the scenario to unfold. As the low interest rates of the early part of the decade evolved into one big easy-money lending orgy, investors' perceptions of risk went down, not up. Fairfax's CDS bets were down 74% by the end of 2006. "But we still held it," Watsa said, "and we took a deep breath and bought some more."
http://www.theglobeandmail.com/report-on-business/the-reluctant-ceo-of-the-year/article723688/singlepage/
Ireland has solid fundamentals, says Fairfax of bank investment
http://www.thestar.com/business/article/1032071--ireland-has-solid-fundamentals-says-fairfax-of-bank-investment
When Fairfax CEO Prem Watsa betted against US HOUSING back in 2008 nobody believed him..but he made billions for his firm.
LOCKED TIGHT AT 1.40LOWER BOTTOM
AMEX: ULU Going up15% everyday ...
ULU insider buying ? AMEX : ULU heading for USFDA approval anytime soon...90days approval time
http://www.uluruinc.com/press_releases/ULURU_Inc_Announces_Filing_of_...
OPPORTUNITY @2.75 WHEN OTHERS ARE FEARED ...........$16 is the ultimate price not too far 30 days from now....
ONLY FYI ...RELEASED TODAY EVENING(17:59)BY BANK OF IRELAND
IF GOLDMAN SACHS IS TO INVEST !!!!! THIS WOULD BE DOUBLE FIGURE !!!
Department of Finance nor the bank will comment on the identity of the investors. The State was advised on the deal by Goldman Sachs.
http://www.rte.ie/news/2011/0725/boi.html
So it was true PREMARKET WAS $1
AS OF MARCH 2011...
http://www.leonhardtventures.com/img/Bioheart_Corporate_Profile_Mar_2011.pdf
The US FDA has approved a phase I clinical trial for MyoCell SDF-1 (Stromal Derived Factor - 1) to treat congestive heart
failure. The REGEN trial will enroll 15 patients in a multicenter, randomized, dose escalation study to assess the safety and cardiovascular effects of the implantation of MyoCell SDF-1 in congestive heart failure patients post myocardial infarction.
This will be the world’s first clinical trial to test a combination gene and cell therapy for cardiovascular disease.
http://www.cardiologyonline.com/wchd11/Final%20Program.pdf
JULY 25TH PAGE........
15:00 MYOBLAST TRANSPLANTATION FOR HEART REPAIR 345
H.J. Leonhardt , Bioheart Inc., Sunrise, FL, USA
If the results of the MARVEL Clinical Program demonstrate statistically significant evidence of the safety and efficacy of MyoCell, we anticipate having a basis to ask the FDA to consider the MARVEL Trial a pivotal trial.
If the REGEN Trial exhibits the same level of increased efficacy vs. MyoCell alone in humans as was seen in animals, consideration will be given to including MyoCell with SDF-1 in the MARVEL trial, which is currently on hold pending the REGEN Trial.
The SEISMIC (European), MYOHEART and MARVEL Trials have been designed to test the safety and efficacy of MyoCell in treating patients with severe, chronic damage to the heart. Upon regulatory approval of MyoCell, we intend to generate revenue from the sale of MyoCell cell-culturing services for treatment of patients by interventional cardiologists.
http://www.bioheartinc.com/clinicalprograms.html
http://www.cardiologyonline.com/wchd11/Final%20Program.pdf
If insiders are loaded with million shares in last 6 months there is something big coming up..
http://www.marketwatch.com/investing/stock/BHRT/insideractions
ASKING MAY GO UPTO $1
INSIDERS LOADED WITH SHARES BUY...
Date
Insider
Shares
Transaction
Value
4/6/11
AHN, SAMUEL S,
Director
97,400
Buy at $0.154 per share.
$15,000
3/31/11
AHN, SAMUEL S,
Director
163,400
Buy at $0.153 per share.
$25,000
3/29/11
AHN, SAMUEL S,
Director
167,790
Buy at $0.149 per share.
$25,001
3/28/11
AHN, SAMUEL S,
Director
246,480
Buy at $0.142 per share.
$35,000
12/13/10
HART, CHARLES ARNOLD,
Director
675,580
Buy at $0.15 per share.
$101,337
11/30/10
MURPHY, WILLIAM P., JR.,
Director
6,159,080
Buy at $0.15 per share.
$923,862
11/30/10
HART, CHARLES ARNOLD,
Director
180,620
Buy at $0.15 per share.
$27,093
Date
Insider
Shares
Transaction
Value
4/6/11
AHN, SAMUEL S,
Director
97,400
Buy at $0.154 per share.
$15,000
3/31/11
AHN, SAMUEL S,
Director
163,400
Buy at $0.153 per share.
$25,000
3/29/11
AHN, SAMUEL S,
Director
167,790
Buy at $0.149 per share.
$25,001
3/28/11
AHN, SAMUEL S,
Director
246,480
Buy at $0.142 per share.
$35,000
12/13/10
HART, CHARLES ARNOLD,
Director
675,580
Buy at $0.15 per share.
$101,337
11/30/10
MURPHY, WILLIAM P., JR.,
Director
6,159,080
Buy at $0.15 per share.
$923,862
11/30/10
HART, CHARLES ARNOLD,
Director
180,620
Buy at $0.15 per share.
$27,093
Date
Insider
Shares
Transaction
Value
4/6/11
AHN, SAMUEL S,
Director
97,400
Buy at $0.154 per share.
$15,000
3/31/11
AHN, SAMUEL S,
Director
163,400
Buy at $0.153 per share.
$25,000
3/29/11
AHN, SAMUEL S,
Director
167,790
Buy at $0.149 per share.
$25,001
3/28/11
AHN, SAMUEL S,
Director
246,480
Buy at $0.142 per share.
$35,000
12/13/10
HART, CHARLES ARNOLD,
Director
675,580
Buy at $0.15 per share.
$101,337
11/30/10
MURPHY, WILLIAM P., JR.,
Director
6,159,080
Buy at $0.15 per share.
$923,862
11/30/10
HART, CHARLES ARNOLD,
Director
180,620
Buy at $0.15 per share.
$27,093
BHRT authorized number of shares of common stock is to be raised from
75,000,000 to 195,000,000 and the increase should be effected on or
shortly after 20 days following the mailing of this Information
Statement to the stockholders. However, the filing does not say when
the statement has been mailed to the shareholders.
Phase-II is still required to be carried out before BLA with FDA..
All other trials are closed since 2009.
http://www.bioheartinc.com/clinical.php